TY - JOUR
T1 - Update on the Therapeutic Management of Hepatic Encephalopathy
AU - Kornerup, Linda Skibsted
AU - Gluud, Lise Lotte
AU - Vilstrup, Hendrik
AU - Dam, Gitte
PY - 2018
Y1 - 2018
N2 - PURPOSE OF REVIEW: Hepatic encephalopathy (HE) is a common and devastating complication to chronic liver disease. In this paper, we summarize the latest research and evidence of both conventional and up-coming treatments.RECENT FINDINGS: Meta-analyses report beneficial effects of lactulose, branched-chain amino acids, rifaximin, and to some degree L-ornithine L-aspartate on the manifestations of HE in patients with cirrhosis, and generally the numbers needed to treat are low. Recent studies on newer HE treatments including ornithine phenylacetate, spherical carbon, and fecal microbiota transplant also report potentially beneficial effects on HE manifestations. The conventional treatments benefit patients with HE. Newer treatments are under study and more research is needed for their validation.
AB - PURPOSE OF REVIEW: Hepatic encephalopathy (HE) is a common and devastating complication to chronic liver disease. In this paper, we summarize the latest research and evidence of both conventional and up-coming treatments.RECENT FINDINGS: Meta-analyses report beneficial effects of lactulose, branched-chain amino acids, rifaximin, and to some degree L-ornithine L-aspartate on the manifestations of HE in patients with cirrhosis, and generally the numbers needed to treat are low. Recent studies on newer HE treatments including ornithine phenylacetate, spherical carbon, and fecal microbiota transplant also report potentially beneficial effects on HE manifestations. The conventional treatments benefit patients with HE. Newer treatments are under study and more research is needed for their validation.
KW - Amino Acids, Branched-Chain/therapeutic use
KW - Anti-Bacterial Agents/therapeutic use
KW - Disease Management
KW - Fecal Microbiota Transplantation
KW - Gastrointestinal Agents/therapeutic use
KW - Hepatic Encephalopathy/drug therapy
KW - Humans
KW - Lactulose/therapeutic use
KW - Probiotics/therapeutic use
KW - Rifamycins/therapeutic use
KW - Rifaximin
U2 - 10.1007/s11894-018-0627-8
DO - 10.1007/s11894-018-0627-8
M3 - Review
C2 - 29644492
VL - 20
JO - Current Gastroenterology Reports
JF - Current Gastroenterology Reports
SN - 1534-312X
IS - 5
M1 - 21
ER -